Segall Bryant & Hamill LLC Raises Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Segall Bryant & Hamill LLC increased its position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) by 43.4% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 193,459 shares of the company’s stock after acquiring an additional 58,522 shares during the quarter. Segall Bryant & Hamill LLC’s holdings in SpringWorks Therapeutics were worth $6,990,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in shares of SpringWorks Therapeutics by 6.6% in the fourth quarter. Vanguard Group Inc. now owns 7,158,871 shares of the company’s stock worth $258,650,000 after purchasing an additional 445,593 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in SpringWorks Therapeutics in the 4th quarter valued at approximately $455,000. Teacher Retirement System of Texas raised its holdings in SpringWorks Therapeutics by 26.4% during the 4th quarter. Teacher Retirement System of Texas now owns 17,609 shares of the company’s stock valued at $636,000 after acquiring an additional 3,674 shares during the period. Platinum Investment Management Ltd. purchased a new stake in shares of SpringWorks Therapeutics during the fourth quarter worth $1,694,000. Finally, Cibc World Markets Corp bought a new position in shares of SpringWorks Therapeutics in the fourth quarter worth $232,000.

SpringWorks Therapeutics Trading Down 1.5 %

Shares of NASDAQ SWTX opened at $46.48 on Thursday. The business has a 50-day moving average of $47.48 and a 200-day moving average of $39.63. The firm has a market capitalization of $3.48 billion, a price-to-earnings ratio of -13.36 and a beta of 0.76. SpringWorks Therapeutics, Inc. has a 12 month low of $28.21 and a 12 month high of $62.00.

SpringWorks Therapeutics (NASDAQ:SWTX) last issued its quarterly earnings results on Thursday, February 20th. The company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.38). SpringWorks Therapeutics had a negative return on equity of 46.74% and a negative net margin of 134.73%. The company had revenue of $61.55 million during the quarter, compared to the consensus estimate of $60.53 million. On average, analysts predict that SpringWorks Therapeutics, Inc. will post -2.05 earnings per share for the current year.

Analyst Upgrades and Downgrades

SWTX has been the topic of a number of analyst reports. Wedbush reissued an “outperform” rating and set a $81.00 price objective on shares of SpringWorks Therapeutics in a report on Thursday, February 20th. Guggenheim lowered their price target on shares of SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a report on Wednesday, January 8th. HC Wainwright restated a “buy” rating and issued a $74.00 price objective on shares of SpringWorks Therapeutics in a research report on Friday, February 21st. Finally, Evercore ISI upped their target price on shares of SpringWorks Therapeutics from $60.00 to $65.00 and gave the stock an “outperform” rating in a report on Wednesday, February 12th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, SpringWorks Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $73.20.

Insider Buying and Selling at SpringWorks Therapeutics

In related news, CEO Saqib Islam sold 48,000 shares of the firm’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $53.30, for a total transaction of $2,558,400.00. Following the transaction, the chief executive officer now directly owns 1,002,502 shares of the company’s stock, valued at approximately $53,433,356.60. This trade represents a 4.57 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Daniel Pichl sold 29,750 shares of the company’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $54.36, for a total value of $1,617,210.00. Following the completion of the sale, the insider now directly owns 50,762 shares of the company’s stock, valued at approximately $2,759,422.32. This represents a 36.95 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 440,766 shares of company stock worth $24,402,956 over the last 90 days. Corporate insiders own 7.61% of the company’s stock.

SpringWorks Therapeutics Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.